High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): a multicentre randomised trial of 100 patients.


Journal

British journal of sports medicine
ISSN: 1473-0480
Titre abrégé: Br J Sports Med
Pays: England
ID NLM: 0432520

Informations de publication

Date de publication:
Mar 2020
Historique:
received: 08 08 2018
revised: 22 01 2019
accepted: 24 01 2019
pubmed: 13 2 2019
medline: 29 2 2020
entrez: 13 2 2019
Statut: ppublish

Résumé

Exercise is considered important in the management of patients with rheumatic diseases, but the effect of high intensity exercises on disease activity is unknown. To investigate the effectiveness of high intensity exercises on disease activity in patients with axial spondyloarthritis (axSpA). Assessor blinded multicentre randomised controlled trial. 100 patients (aged from their 20s to their 60s) with axSpA were randomly assigned to an exercise group or to a no-intervention control group. The exercise group performed cardiorespiratory and muscular strength exercises at high intensity over 3 months. The control group received standard care and was instructed to maintain their usual physical activity level. Primary outcome was disease activity measured with the Ankylosing Spondylitis (AS) Disease Activity Scale (ASDAS, higher score=worst) and the Bath AS Disease Activity Index (BASDAI, 0-10, 10=worst). Secondary outcomes were inflammatory markers, physical function and cardiovascular (CV)-health. There was patient involvement in the design and reporting of this study. 97 of the 100 (97%) randomised patients completed the measurements after the intervention. There was a significant treatment effect of the intervention on the primary outcome (ASDAS: -0.6 [-0.8 to -0.3], p<0.001 and BASDAI: -1.2 [-1.8 to -0.7], p<0.001). Significant treatment effects were also seen for inflammation, physical function and CV-health. High intensity exercises reduced disease symptoms (pain, fatigue, stiffness) and also inflammation in patients with axSpA. It improves patients' function and CV health. This debunks concerns that high intensity exercise might exacerbate disease activity in patients with axSpA. NCT02356874.

Sections du résumé

BACKGROUND BACKGROUND
Exercise is considered important in the management of patients with rheumatic diseases, but the effect of high intensity exercises on disease activity is unknown.
OBJECTIVE OBJECTIVE
To investigate the effectiveness of high intensity exercises on disease activity in patients with axial spondyloarthritis (axSpA).
METHOD METHODS
Assessor blinded multicentre randomised controlled trial. 100 patients (aged from their 20s to their 60s) with axSpA were randomly assigned to an exercise group or to a no-intervention control group. The exercise group performed cardiorespiratory and muscular strength exercises at high intensity over 3 months. The control group received standard care and was instructed to maintain their usual physical activity level. Primary outcome was disease activity measured with the Ankylosing Spondylitis (AS) Disease Activity Scale (ASDAS, higher score=worst) and the Bath AS Disease Activity Index (BASDAI, 0-10, 10=worst). Secondary outcomes were inflammatory markers, physical function and cardiovascular (CV)-health. There was patient involvement in the design and reporting of this study.
RESULTS RESULTS
97 of the 100 (97%) randomised patients completed the measurements after the intervention. There was a significant treatment effect of the intervention on the primary outcome (ASDAS: -0.6 [-0.8 to -0.3], p<0.001 and BASDAI: -1.2 [-1.8 to -0.7], p<0.001). Significant treatment effects were also seen for inflammation, physical function and CV-health.
CONCLUSION CONCLUSIONS
High intensity exercises reduced disease symptoms (pain, fatigue, stiffness) and also inflammation in patients with axSpA. It improves patients' function and CV health. This debunks concerns that high intensity exercise might exacerbate disease activity in patients with axSpA.
TRIAL REGISTRATION NUMBER BACKGROUND
NCT02356874.

Identifiants

pubmed: 30745314
pii: bjsports-2018-099943
doi: 10.1136/bjsports-2018-099943
doi:

Banques de données

ClinicalTrials.gov
['NCT02356874']

Types de publication

Journal Article Multicenter Study Randomized Controlled Trial

Langues

eng

Sous-ensembles de citation

IM

Pagination

292-297

Commentaires et corrections

Type : CommentIn
Type : CommentIn

Informations de copyright

© Author(s) (or their employer(s)) 2020. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Silje Halvorsen Sveaas (SH)

National Advisory Unit for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Annelie Bilberg (A)

Institute of Neuroscience and Physiology, Section of Health and Rehabilitation, Physiotherapy, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.

Inger Jorid Berg (IJ)

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Sella Arrestad Provan (SA)

Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Silvia Rollefstad (S)

Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemme Hospital, Oslo, Norway.

Anne Grete Semb (AG)

Preventive Cardio-Rheuma clinic, Department of Rheumatology, Diakonhjemme Hospital, Oslo, Norway.

Kåre Birger Hagen (KB)

National Advisory Unit for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Melissa Woll Johansen (MW)

Department of Physiotherapy, Martina Hansens Hospital, Bærum, Norway.

Elisabeth Pedersen (E)

Department of Physiotherapy, University Hospital of North Norway, Tromsø, Norway.

Hanne Dagfinrud (H)

National Advisory Unit for Rehabilitation in Rheumatology, Department of Rheumatology, Diakonhjemmet Hospital, Oslo, Norway.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH